{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:24:07Z","timestamp":1792268647192,"version":"4.4.0"},"reference-count":270,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002418","name":"Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences and Peking Union Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.apsb.2025.10.002","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:06:29Z","timestamp":1760141189000},"page":"137-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The progress and perspective of nanomedicine in modulating the tumor immune microenvironment"],"prefix":"10.1016","volume":"16","author":[{"given":"Nan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8237-8813","authenticated-orcid":false,"given":"Jiaming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.10.002_bib1","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.apsb.2024.03.022","article-title":"Engineering nanomedicines for immunogenic eradication of cancer cells: recent trends and synergistic approaches","volume":"14","author":"Elzoghby","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib2","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1038\/s41467-023-42509-7","article-title":"Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.002_bib3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.apsb.2023.12.003","article-title":"Targeting the Warburg effect: a revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer","volume":"14","author":"Liao","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122463","article-title":"Nano-enhanced immunotherapy: targeting the immunosuppressive tumor microenvironment","volume":"305","author":"Jin","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.002_bib5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41401-020-0424-4","article-title":"Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.10.002_bib6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41578-021-00315-x","article-title":"Multifunctional biomolecule nanostructures for cancer therapy","volume":"6","author":"Wang","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","article-title":"Phenotypic and functional separation of memory and effector human CD8+ T cells","volume":"186","author":"Hamann","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-Specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.10.002_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.10.002_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations (\u2217)","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.immunol.26.021607.090404","article-title":"Death by a thousand cuts: granzyme pathways of programmed cell death","volume":"26","author":"Chowdhury","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.10.002_bib21","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood-2012-09-378653","article-title":"Essentials of Th17 cell commitment and plasticity","volume":"121","author":"Muranski","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.10.002_bib22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2014.09.006","article-title":"Tertiary lymphoid structures in cancer and beyond","volume":"35","author":"Dieu-Nosjean","year":"2014","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib24","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/0008-5472.CAN-20-3773","article-title":"Tumor-infiltrating B lymphocyte profiling identifies igG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer","volume":"81","author":"Harris","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nri3754","article-title":"Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?","volume":"14","author":"Kambayashi","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.immuni.2018.08.012","article-title":"B cells are the dominant antigen-presenting cells that activate naive CD4(+) T Cells upon immunization with a virus-derived nanoparticle antigen","volume":"49","author":"Hong","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.10.002_bib27","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.2337\/db12-0006","article-title":"B-cell cross-presentation of autologous antigen precipitates diabetes","volume":"61","author":"Mari\u00f1o","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2025.10.002_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fimmu.2014.00092","article-title":"Early BCR events and antigen capture, processing, and loading on MHC class II on B cells","volume":"5","author":"Avalos","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib29","series-title":"Specific B lymphocytes efficiently pick up, process and present antigen to T cells","first-page":"82","author":"Lanzavecchia","year":"1985"},{"key":"10.1016\/j.apsb.2025.10.002_bib30","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/2326-6066.CIR-20-0432","article-title":"Insights into tumor-associated tertiary lymphoid structures: novel targets for antitumor immunity and cancer immunotherapy","volume":"8","author":"Rodriguez","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12939","article-title":"Regulatory B cells in cancer","volume":"299","author":"Michaud","year":"2021","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2025.10.002_bib32","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2014.10.016","article-title":"Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation","volume":"41","author":"Matsumoto","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.10.002_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2015.02.004","article-title":"B-cells induce regulatory T cells through TGF-\u03b2\/IDO production in a CTLA-4 dependent manner","volume":"59","author":"Nou\u00ebl","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.apsb.2025.10.002_bib34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","article-title":"B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity","volume":"599","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.10.002_bib35","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","article-title":"SnapShot: natural killer cells","volume":"180","author":"Crinier","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-024-00646-3","article-title":"Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance","volume":"10","author":"Liu","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.apsb.2025.10.002_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101652","article-title":"Natural killer cell responses to human oncogenic \u03b3-herpesvirus infections","volume":"60","author":"M\u00fcnz","year":"2022","journal-title":"Semin Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cmi.2014.83","article-title":"The origin and function of tumor-associated macrophages","volume":"12","author":"Liu","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.10.002_bib43","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.4049\/jimmunol.1403215","article-title":"Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs","volume":"194","author":"Sharma","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopen.2016.11.002","article-title":"Initiative action of tumor-associated macrophage during tumor metastasis","volume":"4","author":"Singh","year":"2017","journal-title":"Biochim Open"},{"key":"10.1016\/j.apsb.2025.10.002_bib45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib46","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1039\/D3NR06333J","article-title":"Macrophage-modulating nanomedicine for cancer immunotherapy","volume":"16","author":"Khan","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2025.10.002_bib47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12307-019-00232-2","article-title":"Tumor-Infiltrating immunosuppressive cells in cancer-cell plasticity, tumor progression and therapy response","volume":"12","author":"Lorenzo-Sanz","year":"2019","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.apsb.2025.10.002_bib48","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes","volume":"70","author":"Movahedi","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib50","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/ijc.24859","article-title":"Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma","volume":"126","author":"Abraham","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.3989","article-title":"Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages","volume":"227","author":"Linde","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.apsb.2025.10.002_bib52","doi-asserted-by":"crossref","first-page":"75366","DOI":"10.18632\/oncotarget.12207","article-title":"Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cells","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2025.10.002_bib53","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.10.002_bib54","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1172\/JCI84427","article-title":"The impact of hypoxia on tumor-associated macrophages","volume":"126","author":"Henze","year":"2016","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2025.10.002_bib55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1089\/ars.2016.6695","article-title":"Epigenetic regulation of monocyte and macrophage function","volume":"25","author":"Hoeksema","year":"2016","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.apsb.2025.10.002_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6591703","article-title":"Epigenetic control of macrophage polarisation and soluble mediator gene expression during inflammation","volume":"2016","author":"Kapellos","year":"2016","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.apsb.2025.10.002_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.002_bib58","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1189\/jlb.4RI0515-204R","article-title":"Transcriptional regulation of myeloid-derived suppressor cells","volume":"98","author":"Condamine","year":"2015","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.apsb.2025.10.002_bib59","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.apsb.2023.11.018","article-title":"The emerging tumor microbe microenvironment: from delineation to multidisciplinary approach-based interventions","volume":"14","author":"Fu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib61","doi-asserted-by":"crossref","first-page":"661","DOI":"10.21873\/anticanres.14817","article-title":"Epithelial-to-mesenchymal transition heterogeneity of circulating tumor cells and their correlation with MDSCs and Tregs in HER2-negative metastatic breast cancer patients","volume":"41","author":"Papadaki","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib62","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: key criminals of tumor pre-metastatic niche formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib63","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.10.002_bib64","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","article-title":"Myeloid-derived suppressor cells: linking inflammation and cancer","volume":"182","author":"Ostrand-Rosenberg","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib65","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3(+) Regulatory T Cell heterogeneity and function in autoimmunity and cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.10.002_bib66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib67","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.celrep.2019.12.081","article-title":"Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance","volume":"30","author":"Sullivan","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2025.10.002_bib68","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.10.002_bib70","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib71","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/ni1003","article-title":"Modulation of tryptophan catabolism by regulatory T cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib72","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2025.10.002_bib73","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001680","article-title":"Engineered multifunctional nano- and biological materials for cancer immunotherapy","volume":"10","author":"Brouillard","year":"2021","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib75","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2023.01.051","article-title":"The application of nanoparticles in immunotherapy for hepatocellular carcinoma","volume":"355","author":"Hu","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.002_bib76","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2025.10.002_bib77","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1039\/C8BM01556B","article-title":"Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells","volume":"7","author":"Xie","year":"2019","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2025.10.002_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.10.002_bib79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2013.08.021","article-title":"Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis","volume":"172","author":"Xu","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.002_bib80","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib81","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.1021\/acsnano.5b02829","article-title":"Enrichment and expansion with nanoscale artificial antigen presenting cells for adoptive immunotherapy","volume":"9","author":"Perica","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.002_bib82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.actbio.2023.02.034","article-title":"Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles","volume":"161","author":"Yan","year":"2023","journal-title":"Acta Biomater"},{"key":"10.1016\/j.apsb.2025.10.002_bib83","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.10.002_bib84","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/17425240903085128","article-title":"Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies","volume":"6","author":"Xie","year":"2009","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2025.10.002_bib85","doi-asserted-by":"crossref","first-page":"56731","DOI":"10.1021\/acsami.0c16357","article-title":"Cationic nanoparticle-mediated activation of natural killer cells for effective cancer immunotherapy","volume":"12","author":"Kim","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.002_bib86","article-title":"FoxO transcription factors: applicability as a novel immune cell regulators and therapeutic targets in oxidative stress-related diseases","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.002_bib87","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/aps.2017.125","article-title":"Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy","volume":"39","author":"Hu","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.10.002_bib88","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","article-title":"CAR-T cells: early successes in blood cancer and challenges in solid tumors","volume":"11","author":"Dana","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-1759(94)90012-4","article-title":"Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications","volume":"174","author":"Van Rooijen","year":"1994","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.apsb.2025.10.002_bib90","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate Non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib91","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1039\/D0NH00588F","article-title":"Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer","volume":"6","author":"Liu","year":"2021","journal-title":"Nanoscale Horiz"},{"key":"10.1016\/j.apsb.2025.10.002_bib92","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib93","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib94","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1002\/adfm.201501283","article-title":"Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells","volume":"25","author":"Conde","year":"2015","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib95","doi-asserted-by":"crossref","first-page":"9536","DOI":"10.1021\/acsnano.7b05465","article-title":"Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages","volume":"11","author":"Qian","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.002_bib96","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib97","first-page":"1","article-title":"IgG Fc receptors: evolutionary considerations","volume":"423","author":"Bournazos","year":"2019","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib98","article-title":"Tailoring biomaterials for cancer immunotherapy: emerging trends and future outlook","volume":"29","author":"Wang","year":"2017","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib99","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.7150\/thno.35434","article-title":"Development of adamantane-conjugated TLR7\/8 agonists for supramolecular delivery and cancer immunotherapy","volume":"9","author":"Rodell","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.002_bib100","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","article-title":"One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering","volume":"153","author":"Wang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib101","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nnano.2016.168","article-title":"Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues","volume":"11","author":"Zanganeh","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2025.10.002_bib102","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1039\/C7SC04853J","article-title":"Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy","volume":"9","author":"Zhao","year":"2018","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2025.10.002_bib103","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1021\/acs.nanolett.9b03883","article-title":"Self-delivery micellar nanoparticles prevent premetastatic niche formation by interfering with the early recruitment and vascular destruction of granulocytic myeloid-derived suppressor cells","volume":"20","author":"Long","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.002_bib104","article-title":"Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments","volume":"15","author":"Wang","year":"2022","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.apsb.2025.10.002_bib105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1021\/acs.nanolett.9b03753","article-title":"Pseudoneutrophil cytokine sponges disrupt myeloid expansion and tumor trafficking to improve cancer immunotherapy","volume":"20","author":"Li","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.002_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2022.01.004","article-title":"Biomimetic platelet membrane-coated nanoparticles for targeted therapy","volume":"172","author":"Han","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2025.10.002_bib107","doi-asserted-by":"crossref","first-page":"9850","DOI":"10.1021\/acsami.9b00294","article-title":"Surface-layer protein-enhanced immunotherapy based on cell membrane-coated nanoparticles for the effective inhibition of tumor growth and metastasis","volume":"11","author":"Wu","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.002_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202106682","article-title":"Light-triggered efficient sequential drug delivery of biomimetic nanosystem for multimodal chemo-, antiangiogenic, and anti-MDSC therapy in melanoma","volume":"34","author":"Lai","year":"2022","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2016.11.013","article-title":"Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment","volume":"245","author":"Huo","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.002_bib110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/1535-7163.MCT-17-0981","article-title":"Scavenger receptor type B1 and lipoprotein nanoparticle inhibit myeloid-derived suppressor cells","volume":"17","author":"Plebanek","year":"2018","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2025.10.002_bib111","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.7150\/thno.19987","article-title":"Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency","volume":"7","author":"Kong","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.002_bib112","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201903242","article-title":"A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy","volume":"31","author":"Phuengkham","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib113","doi-asserted-by":"crossref","DOI":"10.1038\/srep28709","article-title":"Efficient nucleic acid delivery to murine regulatory T cells by gold nanoparticle conjugates","volume":"6","author":"Gamrad","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.10.002_bib114","doi-asserted-by":"crossref","first-page":"19355","DOI":"10.1002\/anie.202106392","article-title":"Charge-reversal polymer nano-modulators for photodynamic immunotherapy of cancer","volume":"60","author":"He","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.10.002_bib115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biomaterials.2016.03.007","article-title":"Targeting inhibition of Foxp3 by a CD28 2\u2032-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy","volume":"91","author":"Lozano","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.002_bib116","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41596-020-00421-0","article-title":"Responsive and activable nanomedicines for remodeling the tumor microenvironment","volume":"16","author":"Zhang","year":"2021","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2025.10.002_bib117","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/acscentsci.9b01235","article-title":"M2-Like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKK\u03b2 siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects","volume":"6","author":"Xiao","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2025.10.002_bib118","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib119","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.10.002_bib120","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib121","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.002_bib122","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-134983","article-title":"Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-Cell malignancies","volume":"136","author":"Budde","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.10.002_bib123","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific t-cell-recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib124","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1182\/blood-2022-159524","article-title":"A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 bispecific dart\u00ae molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies","volume":"140","author":"Winer","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.10.002_bib125","first-page":"A1","article-title":"O82 A phase 1 dose escalation study of PRS-343, a HER2\/4\u20131BB bispecific molecule, in patients with HER2-positive malignancies","volume":"8","author":"Piha-Paul","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcS\u00e9-crizotinib trial","volume":"191","author":"Brugi\u00e8res","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib127","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib128","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.2022.40.16_suppl.2643","article-title":"Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor","volume":"40","author":"Schilder","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib129","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2025.10.002_bib130","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1097\/01.HS9.0000968884.66387.cd","article-title":"P494: a first-in-human study of CD123 nk cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, b-cell acute lymphoblastic leukemia or high risk-myelodysplasia","volume":"7","author":"Selwyn Stein","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.apsb.2025.10.002_bib131","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2023.41.16_suppl.2508","article-title":"Phase 1\/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: phase 1 DF1001 monotherapy dose-escalation results","volume":"41","author":"Safran","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib132","article-title":"AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: phase 1\/2a study design and rationale","volume":"40","author":"Santa Gadea","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib133","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1182\/blood-2022-169729","article-title":"The novel bispecific innate cell engager (ICE\u00ae) AFM28 efficiently directs allogeneic nk cells to CD123+ leukemic stem- and progenitor cells in AML","volume":"140","author":"Schmitt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.10.002_bib134","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib135","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.10.002_bib136","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and rituximab in non-hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib137","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291772","article-title":"Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors","volume":"18","author":"Fujikawa","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.10.002_bib139","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s43856-024-00433-x","article-title":"First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors","volume":"4","author":"Mahalingam","year":"2024","journal-title":"Commun Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00277-023-05552-4","article-title":"A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes\/neoplasms or acute myeloid leukemia refractory to hypomethylating agents","volume":"103","author":"Bewersdorf","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.apsb.2025.10.002_bib141","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10637-024-01419-1","article-title":"A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma","volume":"42","author":"Beckermann","year":"2024","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.apsb.2025.10.002_bib142","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008480","article-title":"Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with advanced non-small cell lung cancer","volume":"12","author":"Rajan","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib143","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007552","article-title":"ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment","volume":"11","author":"Ponce","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib144","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1158\/1078-0432.CCR-23-1137","article-title":"Safety, immunologic, and clinical activity of durvalumab in combination with olaparib or cediranib in advanced leiomyosarcoma: results of the DAPPER clinical trial","volume":"29","author":"Salawu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.36401\/JIPO-23-16","article-title":"Phase Ib\/II study of lacnotuzumab in combination with spartalizumab in patients with advanced malignancies","volume":"7","author":"Ahmed","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib146","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3389\/fimmu.2019.01206","article-title":"The reversal of immune exclusion mediated by tadalafil and an anti-tumor vaccine also induces PDL1 upregulation in recurrent head and neck squamous cell carcinoma: interim analysis of a phase i clinical trial","volume":"10","author":"Weed","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.002_bib147","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.10.002_bib148","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.10.002_bib149","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","article-title":"Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study","volume":"10","author":"Brana","year":"2015","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib150","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib151","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib152","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib153","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","article-title":"Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 trial","volume":"27","author":"Bockorny","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib154","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib155","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2021.08.020","article-title":"Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer","volume":"163","author":"Fuh","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib156","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1078-0432.CCR-21-3009","article-title":"ARRY-382 in combination with pembrolizumab in patients with advanced solid tumors: results from a phase 1b\/2 study","volume":"28","author":"Johnson","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib157","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","article-title":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer - the PICCASSO phase I trial","volume":"167","author":"Haag","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib158","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202312436","article-title":"In situ engineering of tumor-associated macrophages via a nanodrug-delivering-drug (\u03b2-Elemene@Stanene) strategy for enhanced cancer chemo-immunotherapy","volume":"62","author":"Chen","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.10.002_bib159","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae(vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.apsb.2025.10.002_bib160","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/mt.2009.126","article-title":"Phase I\/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma","volume":"17","author":"Chawla","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2025.10.002_bib161","doi-asserted-by":"crossref","first-page":"10563","DOI":"10.1200\/jco.2014.32.15_suppl.10563","article-title":"Phase I study of NBTXR3 nanoparticles, in patients with advanced soft tissue sarcoma (STS)","volume":"32","author":"Bonvalot","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib162","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/14737140.7.4.415","article-title":"Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer","volume":"7","author":"Bonomi","year":"2007","journal-title":"Expet Rev Anticancer Ther"},{"key":"10.1016\/j.apsb.2025.10.002_bib163","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","article-title":"Multicenter phase II trial of Genexol-PM, a novel cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"18","author":"Kim","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib164","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1517\/14656560802677874","article-title":"Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer","volume":"10","author":"Poon","year":"2009","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.apsb.2025.10.002_bib165","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/jco.2009.27.15_suppl.2535","article-title":"A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin","volume":"27","author":"Sankhala","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib166","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.2147\/OTT.S105587","article-title":"Onivyde for the therapy of multiple solid tumors","author":"Zhang","year":"2016","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.apsb.2025.10.002_bib167","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1586\/era.09.69","article-title":"Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma","volume":"9","author":"Meyers","year":"2009","journal-title":"Expet Rev Anticancer Ther"},{"key":"10.1016\/j.apsb.2025.10.002_bib168","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0169-409X(96)00453-X","article-title":"The design and development of DaunoXome\u00ae for solid tumor targeting in vivo","volume":"24","author":"Forssen","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.10.002_bib169","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.002_bib170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.04.021","article-title":"Theranostic AGuIX nanoparticles as radiosensitizer: a phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial)","volume":"160","author":"Verry","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib171","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1158\/1078-0432.CCR-23-3196","article-title":"A phase I trial of nab-paclitaxel\/bevacizumab (AB160) nano-immunoconjugate therapy for gynecologic malignancies","volume":"30","author":"Kalogera","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib172","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13550-019-0509-6","article-title":"A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of (188)Re-liposome in patients with metastatic tumors","volume":"9","author":"Wang","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib173","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-07-1951","article-title":"Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo","volume":"14","author":"Pirollo","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib174","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.10.002_bib175","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/mt.2013.32","article-title":"Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors","volume":"21","author":"Senzer","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2025.10.002_bib176","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/mt.2016.118","article-title":"A phase l study of a tumor-targeted systemic nanodelivery system, SGT-94, in genitourinary cancers","volume":"24","author":"Siefker-Radtke","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2025.10.002_bib177","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","article-title":"Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study","volume":"13","author":"Mamot","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib178","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib179","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","article-title":"Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study","volume":"119","author":"Munster","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2018.12.005","article-title":"A phase I-II study using Rexin-G tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer","volume":"12","author":"Chawla","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.apsb.2025.10.002_bib181","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00262-018-2207-z","article-title":"Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma","volume":"67","author":"Gargett","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2025.10.002_bib182","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-09-C36","article-title":"MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU\/leucovorin (LV): phase I results of a Phase I\/Il study in gastro-esophageal adenocarcinoma, with pharmacokinetics","volume":"8","author":"Senzer","year":"2009","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2025.10.002_bib183","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/jco.2009.27.15_suppl.2535","article-title":"A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin","volume":"27","author":"Sankhala","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2025.10.002_bib184","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1021\/acs.molpharmaceut.7b00997","article-title":"Cationic polymeric nanoparticle delivering CCR2 siRNA to inflammatory monocytes for tumor microenvironment modification and cancer therapy","volume":"15","author":"Shen","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2025.10.002_bib185","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1016\/j.biomaterials.2014.09.007","article-title":"Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy","volume":"35","author":"Zhan","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.002_bib186","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1021\/acs.nanolett.7b01193","article-title":"Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy","volume":"17","author":"Shen","year":"2017","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.002_bib187","doi-asserted-by":"crossref","first-page":"52402","DOI":"10.1021\/acsami.0c15983","article-title":"Targeting tumor-associated macrophages by MMP2-sensitive apoptotic body-mimicking nanoparticles","volume":"12","author":"Liu","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.002_bib188","doi-asserted-by":"crossref","first-page":"57798","DOI":"10.1021\/acsami.0c19301","article-title":"Specifically eliminating tumor-associated macrophages with an extra- and intracellular stepwise-responsive nanocarrier for inhibiting metastasis","volume":"12","author":"Guo","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.002_bib189","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1021\/acs.biomac.8b00239","article-title":"ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy","volume":"19","author":"Liu","year":"2018","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.apsb.2025.10.002_bib190","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.002_bib191","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.apsb.2023.07.025","article-title":"Advanced nano-based strategies for mRNA tumor vaccine","volume":"14","author":"Qu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib192","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.apsb.2022.11.026","article-title":"Lipid carriers for mRNA delivery","volume":"13","author":"Zhang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib193","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1021\/acs.nanolett.7b03756","article-title":"Reprogramming tumor-associated macrophages to reverse EGFR(T790M) resistance by dual-targeting codelivery of gefitinib\/vorinostat","volume":"17","author":"Peng","year":"2017","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.002_bib194","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2011.11.013","article-title":"Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy","volume":"158","author":"Huang","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.002_bib195","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.7150\/thno.42385","article-title":"Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel","volume":"10","author":"Dai","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.002_bib196","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jconrel.2020.04.037","article-title":"Versatile activatable vSIRP\u03b1-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells","volume":"323","author":"Ko","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.002_bib197","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib198","doi-asserted-by":"crossref","first-page":"17285","DOI":"10.1021\/acsami.4c01451","article-title":"Proton sponge nanocomposites for synergistic tumor elimination via autophagy inhibition-promoted cell apoptosis and macrophage repolarization-enhanced immune response","volume":"16","author":"Duan","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.002_bib199","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1021\/acs.nanolett.8b02321","article-title":"Engineering PD-1-presenting platelets for cancer immunotherapy","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.002_bib200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/nnm-2019-0190","article-title":"Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy","volume":"15","author":"Chen","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2025.10.002_bib201","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acsnano.0c05194","article-title":"Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors","volume":"14","author":"Mei","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.002_bib202","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/acs.nanolett.8b04296","article-title":"Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating t cells and potentiates anti-PD-1 therapy","volume":"19","author":"Zhang","year":"2019","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.002_bib203","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/pharmaceutics15112606","article-title":"Harnessing nanomedicine to potentiate the chemo-immunotherapeutic effects of doxorubicin and alendronate co-encapsulated in pegylated liposomes","volume":"15","author":"Gabizon","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.002_bib204","article-title":"Chimeric peptide-engineered self-delivery nanomedicine for photodynamic-triggered breast cancer immunotherapy by macrophage polarization","author":"Liu","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.002_bib205","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202210487","article-title":"An ion-enhanced oncolytic virus-like nanoparticle for tumor immunotherapy","volume":"61","author":"Wu","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.10.002_bib206","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1021\/acs.bioconjchem.2c00407","article-title":"Colistin crosslinked gemcitabine micelles to eliminate tumor drug resistance caused by intratumoral microorganisms","volume":"33","author":"Qiu","year":"2022","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.10.002_bib207","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.apsb.2023.08.024","article-title":"Emerging delivery systems based on aqueous two-phase systems: a review","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib208","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202170304","article-title":"Engineering endogenous tumor-associated macrophage-targeted biomimetic nano-RBC to reprogram tumor immunosuppressive microenvironment for enhanced chemo-immunotherapy","volume":"33","author":"Wang","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib209","doi-asserted-by":"crossref","first-page":"eaan3682","DOI":"10.1126\/scitranslmed.aan3682","article-title":"In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy","volume":"10","author":"Wang","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.10.002_bib210","article-title":"Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy","volume":"6","author":"Li","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2025.10.002_bib211","doi-asserted-by":"crossref","first-page":"14424","DOI":"10.1021\/acsnano.2c12498","article-title":"Multifunctional redox-responsive nanoplatform with dual activation of macrophages and t cells for antitumor immunotherapy","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.002_bib212","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.2147\/IJN.S450205","article-title":"Regulating tumor-associated macrophage polarization by cyclodextrin-modified PLGA nanoparticles loaded with R848 for treating colon cancer","volume":"19","author":"Yuan","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.002_bib213","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/IJN.S450283","article-title":"Preclinical efficacy of cabazitaxel loaded poly(2-alkyl cyanoacrylate) nanoparticle variants","volume":"19","author":"Valsalakumari","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.002_bib214","article-title":"Engineered extracellular vesicles expressing siglec-10 camouflaged AIE photosensitizer to reprogram macrophages to active M1 phenotype and present tumor-associated antigens for photodynamic immunotherapy","volume":"20","author":"Sun","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.002_bib215","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2023.12.058","article-title":"Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer","volume":"366","author":"Chen","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.002_bib216","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1039\/D1BM01053K","article-title":"Injectable shear-thinning polylysine hydrogels for localized immunotherapy of gastric cancer through repolarization of tumor-associated macrophages","volume":"9","author":"Yang","year":"2021","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2025.10.002_bib217","doi-asserted-by":"crossref","first-page":"9963","DOI":"10.1016\/j.biomaterials.2014.08.036","article-title":"Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal\/immune cancer therapy","volume":"35","author":"Tao","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.002_bib218","article-title":"Bypassing the immunosuppression of myeloid-derived suppressor cells by reversing tumor hypoxia using a platelet-inspired platform","volume":"30","author":"Zhang","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib219","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202004240","article-title":"Nanoparticle-enabled dual modulation of phagocytic signals to improve macrophage-mediated cancer immunotherapy","volume":"16","author":"Zhang","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.002_bib220","article-title":"Adipocytes encapsulating telratolimod recruit and polarize tumor-associated macrophages for cancer immunotherapy","volume":"10","author":"Wen","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.10.002_bib221","article-title":"Engineered microparticles for treatment of murine brain metastasis by reprograming tumor microenvironment and inhibiting MAPK Pathway","volume":"10","author":"Lu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.10.002_bib222","doi-asserted-by":"crossref","first-page":"42566","DOI":"10.1021\/acsami.7b13594","article-title":"A dual macrophage targeting nanovector for delivery of oligodeoxynucleotides to overcome cancer-associated immunosuppression","volume":"9","author":"He","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.002_bib223","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12951-023-01820-7","article-title":"Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma","volume":"21","author":"Yuan","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.002_bib224","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/asia.201900574","article-title":"Multifunctional DNA origami nanoplatforms for drug delivery","volume":"14","author":"Lu","year":"2019","journal-title":"Chem Asian J"},{"key":"10.1016\/j.apsb.2025.10.002_bib225","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1021\/acsabm.1c00285","article-title":"Multifunctional carbon monoxide prodrug-loaded nanoplatforms for effective photoacoustic imaging-guided photothermal\/gas synergistic therapy","volume":"4","author":"Lin","year":"2021","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib226","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1039\/D1NR01096D","article-title":"Multifunctional pathology-mapping theranostic nanoplatforms for US\/MR imaging and ultrasound therapy of atherosclerosis","volume":"13","author":"Gao","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2025.10.002_bib227","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.7150\/thno.34941","article-title":"Theranostics in immuno-oncology using nanobody derivatives","volume":"9","author":"Lecocq","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.002_bib228","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7150\/thno.48811","article-title":"MRI-traceable theranostic nanoparticles for targeted cancer treatment","volume":"11","author":"Anani","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.002_bib229","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/pharmaceutics14071460","article-title":"Immune checkpoint inhibitor-mediated cancer theranostics with radiolabeled anti-granzyme B peptide","volume":"14","author":"de Aguiar Ferreira","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.002_bib230","doi-asserted-by":"crossref","first-page":"55780","DOI":"10.1021\/acsami.1c12611","article-title":"Tumor microenvironment-activated theranostics nanozymes for fluorescence imaging and enhanced chemo-chemodynamic therapy of tumors","volume":"13","author":"Zhao","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.002_bib231","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14998","article-title":"Dual-stimuli responsive and reversibly activatable theranostic nanoprobe for precision tumor-targeting and fluorescence-guided photothermal therapy","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.002_bib232","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acsnano.6b07525","article-title":"Theranostic liposomes with hypoxia-activated prodrug to effectively destruct hypoxic tumors post-photodynamic therapy","volume":"11","author":"Feng","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.002_bib233","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2174\/0122117385300471240408063205","article-title":"Nano-based theranostics approach in the management of cancer: review","volume":"13","author":"Singh","year":"2025","journal-title":"Pharm Nanotechnol"},{"key":"10.1016\/j.apsb.2025.10.002_bib234","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201901223","article-title":"Size-dependent EPR effect of polymeric nanoparticles on tumor targeting","volume":"9","author":"Kang","year":"2020","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib235","article-title":"Mouse Strain- and charge-dependent vessel permeability of nanoparticles at the lower size limit","volume":"10","author":"Chen","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.apsb.2025.10.002_bib236","article-title":"Design of smart size-, surface-, and shape-switching nanoparticles to improve therapeutic efficacy","volume":"18","author":"Li","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.002_bib237","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1021\/acs.nanolett.0c02463","article-title":"Surface charge-dependent cytotoxicity of plastic nanoparticles in alveolar cells under cyclic stretches","volume":"20","author":"Roshanzadeh","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.002_bib238","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1788","article-title":"Influence of surface chemistry and morphology of nanoparticles on protein corona formation","volume":"14","author":"Bilardo","year":"2022","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.002_bib239","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002852","article-title":"STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation","volume":"9","author":"Nakamura","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib240","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2025.10.002_bib241","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2025.10.002_bib242","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8011","article-title":"Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy","volume":"8","author":"Zou","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2025.10.002_bib243","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12951-023-01977-1","article-title":"Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions","volume":"21","author":"Li","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.002_bib244","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.002_bib245","article-title":"Composite scaffolds of gelatin and Fe(3) O(4) nanoparticles for magnetic hyperthermia-based breast cancer treatment and adipose tissue regeneration","volume":"12","author":"Sun","year":"2023","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2025.10.002_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121205","article-title":"Nanoparticle-containing electrospun nanofibrous scaffolds for sustained release of SDF-1\u03b1","volume":"610","author":"Molina-Pe\u00f1a","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.10.002_bib247","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12951-023-02069-w","article-title":"LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion","volume":"21","author":"Xiang","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.002_bib248","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2022.05.056","article-title":"Preparation and application of pH-responsive drug delivery systems","volume":"348","author":"Ding","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.002_bib249","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1080\/10717544.2022.2079771","article-title":"Recent advances in anti-multidrug resistance for nano-drug delivery system","volume":"29","author":"Wang","year":"2022","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2025.10.002_bib250","doi-asserted-by":"crossref","first-page":"7856","DOI":"10.1039\/D2NR02064E","article-title":"Reverse anti-breast cancer drug resistance effects by a novel two-step assembled nano-celastrol medicine","volume":"14","author":"Xiao","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2025.10.002_bib251","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41565-024-01620-6","article-title":"Chimeric nanobody-decorated liposomes by self-assembly","volume":"19","author":"Rahman","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2025.10.002_bib252","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41419-024-06715-5","article-title":"Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers","volume":"15","author":"Georgievski","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.10.002_bib253","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","article-title":"Small interfering RNA for cancer treatment: overcoming hurdles in delivery","volume":"10","author":"Charbe","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib254","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1021\/acsnano.3c11260","article-title":"Nanotechnology reprogramming metabolism for enhanced tumor immunotherapy","volume":"18","author":"Zhou","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.002_bib255","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.2174\/1381612824666180523125144","article-title":"Process intensification techniques for the production of nano- and submicronic particles for food and medical applications","volume":"24","author":"Stoller","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.apsb.2025.10.002_bib256","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.apsb.2021.08.012","article-title":"Pure drug nano-assemblies: a facile carrier-free nanoplatform for efficient cancer therapy","volume":"12","author":"Fu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.002_bib257","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/pharmaceutics14020247","article-title":"The Hitchhiker's guide to human therapeutic nanoparticle development","volume":"14","author":"Ramos","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.002_bib258","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2022.120205","article-title":"Long-term exposure to nanoplastics reshapes the microbial interaction network of activated sludge","volume":"314","author":"Chen","year":"2022","journal-title":"Environ Pollut"},{"key":"10.1016\/j.apsb.2025.10.002_bib259","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12011-018-1477-9","article-title":"Long-term effects of unmodified 50 nm ZnO in mice","volume":"189","author":"Kong","year":"2019","journal-title":"Biol Trace Elem Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib260","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/IJN.S219042","article-title":"New approaches in breast cancer therapy through green nanotechnology and nano-ayurvedic medicine - pre-clinical and pilot human clinical investigations","volume":"15","author":"Khoobchandani","year":"2020","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.002_bib261","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1021\/acs.chemrev.9b00692","article-title":"Single-virus tracking: from imaging methodologies to virological applications","volume":"120","author":"Liu","year":"2020","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2025.10.002_bib262","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2021.132097","article-title":"Effect of metal and metal oxide engineered nano particles on nitrogen bio-conversion and its mechanism: a review","volume":"287","author":"Chen","year":"2022","journal-title":"Chemosphere"},{"key":"10.1016\/j.apsb.2025.10.002_bib263","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006235","article-title":"Adding liposomal doxorubicin enhances the abscopal effect induced by radiation\/\u03b1PD1 therapy depending on tumor cell mitochondrial DNA and cGAS\/STING","volume":"11","author":"Wang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.002_bib264","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.2147\/IJN.S260760","article-title":"Encapsulated checkpoint blocker before chemotherapy: the optimal sequence of anti-CTLA-4 and doxil combination therapy","volume":"15","author":"Alimohammadi","year":"2020","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.002_bib265","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.002_bib266","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.biopha.2008.10.001","article-title":"A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors","volume":"63","author":"Zhang","year":"2009","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.10.002_bib267","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bcpt.12997","article-title":"ABCB1 Variation affects myelosuppression, progression-free survival and overall survival in paclitaxel\/carboplatin-treated Ovarian Cancer patients","volume":"123","author":"Bj\u00f6rn","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.apsb.2025.10.002_bib268","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semcancer.2019.11.002","article-title":"Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy","volume":"69","author":"Raj","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.apsb.2025.10.002_bib269","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.002_bib270","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.3390\/ijms25063126","article-title":"Biomaterials in drug delivery: advancements in cancer and diverse therapies-review","volume":"25","author":"Drabczyk","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:50:31Z","timestamp":1771509031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525006756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":270,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2211383525006756"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.10.002","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The progress and perspective of nanomedicine in modulating the tumor immune microenvironment","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}